Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the Women's Health Initiative randomised placebo-controlled trial

Authors

Garnet L. Anderson, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA
Rowan T. Chlebowski, University of California, Los Angeles
Aaron K. Aragaki, Fred Hutchinson Cancer Research Center, Public Health Sciences, Seattle, WA
Lewis H. Kuller, University of Pittsburgh
Joann E. Manson, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Margery Gass, North American Menopause Society, Cleveland, OH
Elizabeth Bluhm, Medstar Research Institute, Hyattsville, MD
Stephanie Connelly, University of Tennessee
F. Allan Hubbell,, University of California-Irvine
Dorothy Lane, Stony Brook University School of Medicine
Lisa Martin, George Washington UniversityFollow
Judith Ockene, University of Massachusetts
Thomas Rohan, Albert Einstein College of Medicine, Bronx, NY
Robert Schenken, University of Texas
Jean Wactawski-Wende, University at Buffalo

Document Type

Journal Article

Publication Date

5-2012

Journal

The Lancet Oncology

Volume

Volume 13, Issue 5

Inclusive Pages

476-486

Keywords

Breast Neoplasms--epidemiology; Estrogens; Conjugated (USP)--administration & dosage

Comments

This is an open access PubMed Central article. Click on link for full-text access.

APA Citation

Anderson, G., Chlebowski, R., Aragaki, A., Kuller, L., Manson, J., Gass, M., Bluhm, E., & Connelly, S. (2012). Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: Extended follow-up of the women. The Lancet Oncology, 13(5), 476-486.

Peer Reviewed

1

Open Access

1